SU1740001A1 - Method for treating the atopic forms of bronchial asthma - Google Patents
Method for treating the atopic forms of bronchial asthma Download PDFInfo
- Publication number
- SU1740001A1 SU1740001A1 SU874284781A SU4284781A SU1740001A1 SU 1740001 A1 SU1740001 A1 SU 1740001A1 SU 874284781 A SU874284781 A SU 874284781A SU 4284781 A SU4284781 A SU 4284781A SU 1740001 A1 SU1740001 A1 SU 1740001A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- remission
- days
- bronchial asthma
- duration
- treatment
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к медицине, в частности к детской пульмонологии и аллергологии . Цель - удлинение ремиссии заболевани и сокращение продолжительности лечени у детей. Дл этого дет м с атонической формой бронхиальной астмы в периоде ремиссии ввод т димефосфон в возрастной дозировке в течение 10-14 дней. Апробаци способа у 22 больных атонической формы бронхиальной астмы показало , что использование димефосфона увеличивает продолжительность ремиссии в среднем до 189 дней. На фоне проводимой терапии наблюдаетс нормализаци уровн циркулирующих иммунных комплексов, циклических нуклеотидов. Побочных влений не наблюдалось, а длительность терапии сократилась с-2-4 мес до 10-14 дн.This invention relates to medicine, in particular, pediatric pulmonology and allergology. The goal is to prolong the remission of the disease and reduce the duration of treatment in children. For this purpose, with the atonic form of bronchial asthma, in the period of remission, dimephosphone is administered at an age dosage of 10-14 days. Approbation of the method in 22 patients with atopic form of bronchial asthma showed that the use of dimefosfona increases the duration of remission, on average, up to 189 days. Against the background of the therapy, the level of circulating immune complexes, cyclic nucleotides, is normalized. No adverse events were observed, and the duration of therapy was reduced from 2-4 months to 10-14 days.
Description
Изобретение относитс к медицине, в частности к детской пульмонологии.This invention relates to medicine, in particular to pediatric pulmonology.
Цель изобретени - удлинение ремиссии заболевани и сокращение продолжительности лечени у детей.The purpose of the invention is to prolong the remission of the disease and reduce the duration of treatment in children.
Способ осуществл ют следующим образом .The method is carried out as follows.
Больному ребенку с атонической формой бронхиальной астмы в периоде ремиссии назначают внутрь после еды димефосфон в дозе 30 мг/кг массы тела 3-4 раза в день на курс 10-14 дн.A sick child with an atonic form of bronchial asthma in the period of remission is administered orally after eating dimephosphone at a dose of 30 mg / kg of body weight 3-4 times a day for a course of 10-14 days.
Пример 1. Больна 10 лет. Бронхиальна астма, атоническа , типична , меж приступный период.Example 1. Sick 10 years. Bronchial asthma, atonic, typical, between paroxysmal period.
При обследовании со стороны органов дыхани влени бронхоспэзма отсутствовала . Показатели ПИК70ед.экс., коэффициент аутоиммунизации 3,9. Назначен курс лечени димефосфоном в дозе 30 мг/кг 3When examining the respiratory organs, the occurrence of bronchospesm was absent. Indicators PIK70ed.ex., The coefficient of autoimmunization of 3.9. Treatment was prescribed with dimefosfon at a dose of 30 mg / kg 3
раза в день после еды в течение 10 дн. После лечени циркулирующие иммунные комплексы в пределах нормы (35 ед.экс.), т.е. снизились в 2 раза.once a day after meals for 10 days. After treatment, the circulating immune complexes are within the normal range (35 units), i.e. decreased by 2 times.
Введение в лечение димефосфона способствовало нормализации показателей циркулирующих иммунных комплексов. Ремисси удлинилась до 6 мес.Introduction to the treatment of dimefosfona contributed to the normalization of circulating immune complexes. Remissi lengthened to 6 months.
Пример 2. Больна И., 13 лет. Бронхиальна астма, атоническа , межприступ- ный период. Наследственность: мать болеет бронхиальной астмой.Example 2. Ill I., 13 years. Bronchial asthma, atonic, interictal period. Heredity: the mother suffers from asthma.
Во врем осмотра изменений со стороны бронхиальной системы нет. Проведенные функциональные пробы без изменений. цАМФ 10, цГМФ 6,0. После лечени димефосфоном в течение 10 дн произошли изменени в виде цАМФ 13, цГМФ 4,7.During the inspection of changes from the bronchial system is not. Conducted functional tests without changes. cAMP 10, cGMP 6.0. After treatment with dimefosfon for 10 days, there were changes in the form of cAMP 13, cGMP 4.7.
Введение в лечение димефосфона способствовало нормализации показателейIntroduction to the treatment of dimefosfona contributed to the normalization of indicators
22
ОABOUT
о оoh oh
циклических нуклеотидов. Клинический иотсутствовали, а продолжительность курсаcyclic nucleotides. Clinical and absent, and the duration of the course
биохимический эффекты были получены прилечени сократилась с 2-4 мес до 10-14 дн. курсе 10 дн. Ремисси 8 мес. ПобочногоThe biochemical effects were obtained from a reduction from 2-4 months to 10-14 days. course 10 days Remissi 8 months Side
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU874284781A SU1740001A1 (en) | 1987-07-14 | 1987-07-14 | Method for treating the atopic forms of bronchial asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU874284781A SU1740001A1 (en) | 1987-07-14 | 1987-07-14 | Method for treating the atopic forms of bronchial asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1740001A1 true SU1740001A1 (en) | 1992-06-15 |
Family
ID=21319641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU874284781A SU1740001A1 (en) | 1987-07-14 | 1987-07-14 | Method for treating the atopic forms of bronchial asthma |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1740001A1 (en) |
-
1987
- 1987-07-14 SU SU874284781A patent/SU1740001A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Балаболкин И.И. и др. Задитен в лечении аллергических заболеваний у детей. - Педиатри . 1987, № 7, с.95-97. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Allison et al. | IMMUNOLOGICAL OBSERVATIONS ON PATENTS WITH LESCH-NYHAN SYNDROME, AND ON THE ROLE OF DE-NOVO PURINE SYNTHESIS IN LYMPHOCYTE TRANSFORMATION | |
| Kamerbeek et al. | Prussian blue in therapy of thallotoxicosis: an experimental and clinical investigation | |
| Cederholm et al. | Vipera berus bites in children—Experience of early antivenom treatment | |
| RU2008004C1 (en) | Prophylactic and curative agent for treating flu virus b | |
| Dawson | Regulation of blood ammonia. | |
| SU1740001A1 (en) | Method for treating the atopic forms of bronchial asthma | |
| Danks et al. | Severe neonatal citrullinaemia. | |
| Sander et al. | Life‐span and Menkes kinky hair syndrome: report of a 13‐year course of this disease | |
| JPH06199695A (en) | Agent for amelioration and treatment of diabetes | |
| LAU et al. | Mongolian spots in Chinese children | |
| Carswell et al. | Sequential trial of effect of phenobarbitone on serum bilirubin of preterm infants | |
| Cathcart III | The vitamin C treatment of allergy and the normally unprimed state of antibodies | |
| Kramer et al. | Vitamin D milk in the treatment of infantile rickets | |
| ALTURA et al. | Prophylactic administration of antibiotics compromises reticuloendothelial system function and exacerbates shock mortality in rats | |
| SU1261665A1 (en) | Method of treatment of thymomegalia of children | |
| Tompkins et al. | The relief of myotonia by the use of a potassium-binding resin | |
| Szórády | Pantothenic acid: Experimental results and clinical observations | |
| SU1650142A1 (en) | Treatment of vitamin d-resistant rachitis | |
| SU1291149A1 (en) | Method of treatment of perinatal hypoxia | |
| US3496267A (en) | Pharmaceutical compositions containing lyophilized cardiac mitochondria | |
| RU2256460C2 (en) | Method for treating inspecific bronchopneumonia in calves | |
| SU1680186A1 (en) | Method for treating the cases of atopic bronchial asthma | |
| Millard Hank Baig et al. | Renal vascular protection by prostaglandins during hypoxemia in unanesthetized fetal lamb | |
| SU1439501A1 (en) | Method of determining individual sensitivity to levomizol in treatment of asthmatic bronchitis in children | |
| SU1215710A1 (en) | Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis |